Sponsor Dossier
Novartis Pharmaceuticals
Sponsor Dossier for Novartis Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADAKVEO
- Brand: AFINITOR
- Brand: AIMOVIG
- Brand: ALIGEOV
- Brand: AMLODIPINE/VALSARTAN NOVARTIS
- Brand: AMLODIPINE/VALSARTAN/HCT NOVARTIS
- Brand: ARTIGE
- Brand: ATECTURA BREEZHALER
- Device (sponsor): Prefilled syringe/needle
- Device (sponsor): Surgical procedure kit, ophthalmic, medicated, single-use
About
Novartis Pharmaceuticals is an Australian Private Company with ABN 18 004 244 160, registered in NSW. The company is active and has been GST-registered since 2000.
Portfolio
Novartis Pharmaceuticals has 99 brands on the ARTG, of which 88 are indexable and 84 carry a Product Information document. 65 brands are PBS-listed, 42 have a PBAC outcome on record, and 41 have an AusPAR on record. Notable brands include ADAKVEO, AFINITOR, AIMOVIG, ALIGEOV, AMLODIPINE/VALSARTAN NOVARTIS, AMLODIPINE/VALSARTAN/HCT NOVARTIS, ARTIGE, ATECTURA BREEZHALER, AVLOIRE, AZARGA, AZOPT, BEOVU.
Therapeutic focus
— Ophthalmology: 21 brands — Neurology: 17 brands — Oncology: 17 brands — Immunology: 10 brands — Cardiology: 9 brands — Haematology: 6 brands — Respiratory: 5 brands — Infectious Disease: 4 brands — Endocrinology: 3 brands — Rare Disease: 3 brands — Psychiatry: 2 brands — Pain Management: 1 brand — Dermatology: 1 brand
PBS footprint
65 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-07-01, across 42 brands with a PBAC outcome on record. The latest AusPAR is 2026-07-15, across 41 brands with an AusPAR on record.